Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.65 |
| ▸ | NCS1 | P62166 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.53 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.52 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.52 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL939648 | 0.94 | RXFP1 (0.59) | RXFP1NCS1KMT2ATAS2R14KDM4E | |
| SCHEMBL939649 | 0.90 | RXFP1 (0.68) | RXFP1NCS1KDM4EHPGDGAA | |
| SCHEMBL1084999 | 0.89 | RXFP1 (0.64) | RXFP1NCS1KDM4EHPGDAVPR2 | |
| SCHEMBL937307 | 0.88 | RXFP1 (0.52) | RXFP1NCS1KMT2ATAS2R14KDM4E | |
| SCHEMBL12912325 | 0.83 | KCNMA1 (0.73) | KMT2AKDM4EGAAMAPTTSHR | |
| SCHEMBL11789635 | 0.82 | KCNK3 (0.68) | RXFP1KMT2AKDM4EGAAMAPT | |
| SCHEMBL27848838 | 0.81 | KMT2A (0.77) | RXFP1KMT2AGAAMAPTTSHR | |
| SCHEMBL1308706 | 0.81 | KCNMA1 (0.74) | KMT2AKDM4EHPGDGAAMAPT | |
| SCHEMBL11798005 | 0.81 | KMT2A (0.60) | KMT2AKDM4EGAAMAPTTSHR | |
| SCHEMBL2271934 | 0.81 | ACLY (0.64) | KMT2AKDM4EGAAMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343980-B2 | Quinazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-01 | — | — | US | disclosed |
| US-8153642-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153642-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110021495-A1 | QUINAZOLES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-27 | — | — | US | disclosed |
| US-20100160316-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160316-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-24 | — | — | US | disclosed |
| US-7713983-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713983-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-11 | — | — | US | disclosed |
| EP-1608632-B1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2004078733-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160316-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | KCNN3, KCNN2, CACNA1I | RXFP1 3120/4885NCS1 121/4885KMT2A 2608/4885 |
| US-20110021495-A1 | QUINAZOLES USEFUL AS MODULATORS OF ION CHANNELS | KCNN3, CACNA1I, CACNA1B | RXFP1 3493/4885NCS1 114/4885KMT2A 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.